Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VCAM1 | P19320 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 5/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | MERTK | Q12866 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.39 |
| ▸ | ALPG | P10696 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.38 |
| ▸ | MAP2K1 | Q02750 | 2/20 | 0.36 |
| ▸ | IDH1 | O75874 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4844309 | 0.91 | VCAM1 (0.53) | VCAM1MAPK1TSHRMAPTPKM | |
| SCHEMBL4837038 | 0.86 | ATM (0.39) | VCAM1MAPK1MAPTLMNAMERTK | |
| SCHEMBL29527221 | 0.84 | HTT (0.46) | MAPK1MAPTPKMLMNAHTT | |
| SCHEMBL725098 | 0.84 | HTT (0.46) | MAPK1MAPTPKMLMNAHTT | |
| SCHEMBL4844235 | 0.81 | HTT (0.40) | VCAM1MAPTLMNAMERTKHTT | |
| SCHEMBL31690565 | 0.80 | KAT2B (0.46) | VCAM1MAPK1MAPTPKMLMNA | |
| SCHEMBL15485425 | 0.80 | KAT2B (0.46) | VCAM1MAPK1MAPTPKMLMNA | |
| SCHEMBL4380157 | 0.78 | MAPT (0.47) | MAPK1MAPTPKMLMNAHTT | |
| SCHEMBL31495088 | 0.76 | VCAM1 (0.56) | VCAM1MAPK1TSHRMAPTPKM | |
| SCHEMBL23682555 | 0.74 | HTT (0.39) | VCAM1TSHRMAPTLMNAHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7384934-B2 | Piperazine substituted aryl benzodiazepines | ELI LILLY AND COMPANY (US) | 2008-06-10 | — | — | US | disclosed |
| US-7384934-B2 | Piperazine substituted aryl benzodiazepines | ELI LILLY AND COMPANY (US) | 2008-06-10 | — | — | US | disclosed |
| US-7384934-B2 | Piperazine substituted aryl benzodiazepines | ELI LILLY AND COMPANY (US) | 2008-06-10 | — | — | US | disclosed |
| EP-1546134-B1 | PIPERAZINE SUBSTITUTED ARYL BENZODIAZEPINES | LILLY CO ELI (US) | 2007-05-02 | — | — | EP | disclosed |
| EP-1546134-B1 | PIPERAZINE SUBSTITUTED ARYL BENZODIAZEPINES | LILLY CO ELI (US) | 2007-05-02 | — | — | EP | disclosed |
| US-20060084643-A1 | Piperazine substituted aryl benzodiazepines | ELI LILLY AND COMPANY | 2006-04-20 | — | — | US | disclosed |
| EP-1546134-A1 | PIPERAZINE SUBSTITUTED ARYL BENZODIAZEPINES | ELI LILLY AND COMPANY (US) | 2005-06-29 | — | — | EP | disclosed |
| WO-2004014895-A1 | PIPERAZINE SUBSTITUTED ARYL BENZODIAZEPINES | ELI LILLY AND COMPANY (US) | 2004-02-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060084643-A1 | Piperazine substituted aryl benzodiazepines | GABBR1, GABBR2, GABRA5 | VCAM1 3261/4885MAPK1 1631/4885TSHR 62/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.